secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001193125-25-239008
Event type: other_material
Sentiment:  positive
Materiality: 0.72
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint initiates Phase 3 DURAVYU DME program; first patient Q1 2026; dual MOA data
--------------------------------------------------------------------------------

- First patient dosing in pivotal Phase 3 DME trials (COMO and CAPRI) expected Q1 2026; trials enroll ~240 patients each.
- Non-inferiority design vs aflibercept; primary endpoint is BCVA change from baseline at weeks 52 and 56.
- New preclinical data shows vorolanib inhibits IL-6 mediated inflammation via JAK receptors, adding to VEGF blockade.
- Company had positive end-of-Phase 2 meeting with FDA; DURAVYU also in Phase 3 for wet AMD.
- Estimated cash and investments as of Sept 30, 2025 included in investor presentation (not specified).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312525239008/0001193125-25-239008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312525239008/d14832d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-239008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer